Background. World Health Organization (WHO) acute respiratory illness case management guidelines classify children with fast breathing as having pneumonia and recommend treatment with an antibiotic. There is concern that many of these children may not have pneumonia and are receiving antibiotics unnecessarily. This could increase antibiotic resistance in the community. The aim was to compare the clinical outcome at 72 h in children with WHO-defined nonsevere pneumonia when treated with amoxicillin, compared with placebo.
Background. World Health Organization (WHO) acute respiratory illness case management guidelines classify children with fast breathing as having pneumonia and recommend treatment with an antibiotic. There is concern that many of these children may not have pneumonia and are receiving antibiotics unnecessarily. This could increase antibiotic resistance in the community. The aim was to compare the clinical outcome at 72 h in children with WHO-defined nonsevere pneumonia when treated with amoxicillin, compared with placebo.
Methods. We performed a double-blind, randomized, equivalence trial in 4 tertiary hospitals in Pakistan. Nine hundred children aged 2-59 months with WHO defined nonsevere pneumonia were randomized to receive either 3 days of oral amoxicillin (45mg/kg/day) or placebo; 873 children completed the study. All children were followed up on days 3, 5, and 14. The primary outcome was therapy failure defined a priori at 72 h.
Results. In per-protocol analysis at day 3, 31 (7.2%) of the 431 children in the amoxicillin arm and 37 (8.3%) of the 442 in placebo group had therapy failure. This difference was not statistically significant (odds ratio [OR] , .85; 95%CI, .50-1.43; P 5 .60). The multivariate analysis identified history of difficult breathing (OR, 2.86; 95% CI, 1.29-7.23; P 5 .027) and temperature .37.5°C 100°F at presentation (OR, 1.99; 95% CI, 1.37-2.90; P 5 .0001) as risk factors for treatment failure by day 5.
Conclusion. Clinical outcome in children aged 2-59 months with WHO-defined nonsevere pneumonia is not different when treated with an antibiotic or placebo. Similar trials are needed in countries with a high burden of pneumonia to rationalize the use of antibiotics in these communities.
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Pneumonia is one of the major causes of death in children ,5 years of age in developing countries, causing .2 million deaths annually [1] . To reduce the number of pneumonia-related deaths in communities where qualified personnel and diagnostic facilities are often not available, the World Health Organization (WHO) developed case management guidelines based on simple clinical signs followed by empirical treatment [2] . Children with fast breathing only are classified as having nonsevere pneumonia requiring oral antibiotics at home, and children who have lower chest indrawing (LCI) and/ or general danger signs (GDS) are classified as having severe pneumonia and very severe pneumonia, respectively. Both groups require referral to hospital and injectable antibiotics. These guidelines have shown to effectively reduce acute respiratory illness (ARI)-related mortality by 34% [3] in communities where they have been successfully implemented.
However, there are certain concerns regarding these guidelines. Many children classified as having nonsevere pneumonia (cough and fast breathing) have neither clinical pneumonia as assessed by physicians nor pneumonia apparent on chest radiographs [4, 5] . Use of the sign of fast breathing alone for prescribing antibiotics may not be the most judicious from a public health perspective and may lead to the spread of antibiotic resistance.
Fast breathing may be caused by conditins other than pneumonia. Respiratory rate in children is affected by many factors, such as fever. Although WHO guidelines recommend that respiratory rate must be counted when a child is afebrile, calm, and preferably sleeping, in real life situations, such practice is not always possible.
Another longstanding unaddressed issue is the inclusion of many children with wheeze in this algorithm. Data from both developed and developing countries show that wheeze is more common in viral than bacterial infections, particularly respiratory syncytial virus infection [6212] . A Cochrane metaanalysis of infants with bronchiolitis found no difference in clinical outcome with antibiotics, compared with placebo [13] . WHO guidelines do not make a distinction between viral and bacterial pneumonia, because controversy still exists concerning the relative importance of these pathogens. A reliable clinical distinction between bacterial and viral infection has yet to be established, and this issue has been problematic for the program managers, senior researchers, and technical experts and remains to be answered. These children continue to receive antibiotics because of the concern that it may not be safe to do otherwise.
To develop effective guidelines for initial antibiotic treatment, it is essential to have information on the likely causative organism and the pattern of antibiotic resistance. Such studies are expensive and require expertise, which is often lacking in the routine setting of most of the developing countries.
For the aforementioned reasons, there is a need to further elaborate the role of antibiotics in children with cough and fast breathing. To address this issue, we conducted this randomized, double-blind, placebo-controlled equivalence trial of oral amoxicillin versus placebo in children aged 2-59 months with WHO-defined nonsevere pneumonia, taking into account all the necessary safety precautions for their well being.
METHODOLOGY

Study Design and Patients
This double-blind, randomized, placebo-controlled trial was performed in 4 hospitals in 3 cities in Pakistan (Islamabad, Lahore, and Rawalpindi). Children aged 2-59 months with cough, difficult breathing, or both were screened for fast breathing. Children were classified using standard WHO algorithm for ARI (Table 4) [2] . Children classified as having nonsevere pneumonia were included in this study. Children who had underlying chronic illness, had a history of >3 episodes of wheeze or acute bronchial asthma, and had used any antibiotic in appropriate doses during the previous 48 h were excluded. Verbal informed consent was obtained from parents or caregivers. The trial was approved by the institutional ethical review boards of the Pakistan Institute of Medical Sciences, Islamabad, and other participating institutions.
Procedures
Enrolled children were randomly assigned to receive either oral amoxicillin (15 mg/kg every 8 h) or placebo with similar color and consistency in the same volume and were masked with regard to taste and smell to the greatest extent possible (Novartis Pharma). The treatment was continued for 3 days. The randomization scheme was generated by a computer program at ARI Research Cell, Islamabad, with uneven blocks of 4, 6, and 8. Self-adhesive sticking labels with unique identification numbers were prepared in Islamabad. A copy of the randomization list with unique identification numbers was given to a health professional not associated with the study who randomized the study drugs. Drug assignment was concealed from patients, parents, and study personnel. The code was broken after the data analysis. The first dose of the drug was given under supervision by the mother or caregiver in the facility with use of a syringe. Moreover, oral salbutamol and paracetamol were given when required. Study physicians counseled caregivers on the recognition of danger signs and urged them to return to the health facility at any time if the condition of the child deteriorated. All guardians were provided with the cell phone numbers of study personnel for an unscheduled visit.
Hypotheses
The primary hypothesis was that the therapy outcome in those who received amoxicillin should be no different from that in those who received placebo when used for 3 days for the treatment of nonsevere pneumonia in children aged 2-59 months. The study outcome was treatment failure by day 3 ( Table 5 ). The secondary outcomes were treatment failure by day 5 (cumulative treatment failure) and relapse. Relapse of disease was defined as development of any sign of pneumonia 6-14 after fast breathing had initially returned to normal. Clinical resolution was defined as either return of respiratory rate to the normal age-specific range or an improvement by day 3 ( Table 5 ).
Assessment of Patients
Respiratory rate was counted twice for 1 min each in 5 min, preferably when the child was quiet, feeding, or asleep. For assessment, the mean value of the 2 readings, rounded to 2 significant figures, was used. If the difference between the 2 readings was >5 breaths per min, a third reading was taken. The mean was then taken from the 2 readings having a difference of ,5 breaths per min. According to WHO protocol, a wheezy child was given 3 cycles of salbutamol nebulization 15 min apart and was reassessed for fast breathing. To assess the respiratory rate objectively, febrile children were given paracetamol, although it was not always possible to record the respiratory rate in children when they did not have fever. All study personnel responsible for data collection were trained for 3 days in standard ARI patient management and in study methods. A senior pediatrician at each site supervised all procedures
Follow-up of Patients
The study physician assessed every child on day 3 (first followupvisit), day 5 (second follow-up visit), and day 14 (third follow-up visit). Treatment was stopped after 3 days if a child was judged to have clinical resolution defined a priori ( Table 5 ). The study personnel assessed patients who did not come for followup at the specified date on the subsequent day at the child's home. If the child was not available on that day, one more attempt was made to contact them before they were judged to be lost to follow-up. The patient was judged to be compliant if she or he had taken 80% of the required dose since the previous visit. Drug containers were returned at follow-up visits, and the remaining drug was measured using specially designed compliance cards.
Therapy Change
Oral amoxicillin was changed (or started in placebo group) to oral chloramphenicol if the child was declared as treatment failure by day 3, day 5, or at relapse. Children who developed severe pneumonia or very severe pneumonia and/or disease or who did not improve after 48 h of oral chloramphenicol therapy were referred for inpatient treatment with the appropriate injectable antibiotic. Oral cefixime was used for 7 days when injectable therapy was not possible. All children were followed up until completely well.
Statistical Analysis
The sample size was estimated on the basis of equivalence (defined a priori) of a difference of <5% in the treatment failure rates between 2 study groups by day 3. We used a standard [14] . Results of a previous study from the same center reported a 6% treatment failure rate with oral amoxicillin for nonsevere pneumonia among children aged 2-59 months [15] . With 1-sided a of .05, power of 90%, and anticipated loss to follow-up of 8%, the estimated sample size was 422 children per group, rounded to 450 children per group. Data were recorded using autocopy forms. One copy was sent to the coordinating center for data entry. Data were double entered, and validated using Epi Info software, version 6.04 (Centers for Disease Control and Prevention, CDC Atlanta). Epi Info, version 6.04, and SPSS, version 13.0 (SPSS) were used for analysis. The primary outcome was analyzed by intention to treat, with other analyses done per protocol. For the primary outcome, proportion of treatment failure and success for the 2 regimens were estimated and compared. Baseline characteristics of all children in 2 treatment arms, by primary outcome, were presented as frequencies and percentages. As a secondary objective, baseline characteristics between cumulative treatment success and failure groups by day 5 were also compared using the v 2 Children's Hospital, Lahore. Four hundred fifty children each were randomly allocated to the amoxicillin and placebo arms. After exclusion of 19 patients (2 bottles broken, 7 discontinued intervention, and 10 lost to follow-up) from the amoxicillin group and 8 patients (lost to follow-up) from the placebo group, 873 children completed the treatment (431 with oral amoxicillin and 442 with placebo) and were successfully followed up until day 14 ( Figure 1 ). Baseline characteristics of the 2 groups are shown in Table 1 . No statistically significant differences were observed for baseline characteristics between the 2 groups. Five hundred fifty-seven children (63.8%) were male, and 294 children (33.7%) were aged 2-5 months. In the infant group (<12 months), 477 children (83.2%) were breastfed, and 471 (53.9%) had wheeze at the time of enrollment.
At day 3 of follow-up, treatment failed in 31 children (7.2%) in the amoxicillin group and in 37 (8.3%) in the placebo group (Figure 1) . This difference was not statistically significant (OR, .85; 95% CI, .50-1.43; P 5 .52). At day 5, 373 of 400 children in the amoxicillin group and 364 of 405 children in the placebo group were declared to have had treatment success (Figure 1) . Therefore, the cumulative treatment failure rate by day 5 in the amoxicillin group ( 13.5% [58 children]) and in the placebo group (17.6% [78 children]) was not statistically significant (OR, .73; 95% CI, .49-1.07; P 5 .09). According to intention to treat analysis, the primary outcome between the 2 groups on day 3 did not differ significantly, compared with per-protocol analysis (OR, 1.13; 95% CI, .72-1.76; P 5 .44) ( Table 2) .
At the day 14 follow-up visit, 3 of 373 children in the amoxicillin group and 5 of 364 children in placebo group had experienced relapse; however, the difference was not statistically significant (difference, -.6; OR, .58; 95% CI, .11-2.81; P5 .69).
On day 3, the antibiotic was changed (amoxicillin group) or started (placebo group) in 68 children. The most common reason for change or start of antibiotic was development of LCI (n 5 45). The number of children who developed LCI in the amoxicillin (n 5 23) and placebo (n 5 22) groups was similar. Similarly, 8 children in the amoxicillin group and 9 children in the placebo group developed WHO-defined general danger signs, specifically, lack of ability to drink. From day 3 through day 5, an additional 29 children in the placebo group and 20 in the amoxicillin group developed LCI and 7 more children in each group developed general danger signs. A total of 26 enrolled children; 14 in the placebo group and 12 in the amoxicillin group needed hospitalization. All children who failed therapy initially were treated successfully with second-or thirdline antibiotics. No deaths were reported among enrolled children in this study.
The comparison of baseline characteristics of children in the cumulative treatment failure and treatment success groups is shown in In logistic regression analysis of all patients, cumulative treatment failure was associated with history of difficult breathing (OR, 2.86; 95% CI, 1.13-7.23; P 5 .027) and presence of temperature .100 0 F measured at the time of enrollment (OR, 1.99; 95% CI, 1.37-2.90; P 5 .0001).
DISCUSSION
In the present study, we revealed that therapy failure rates among children aged 2-59 months with WHO-defined nonsevere pneumonia who were treated with amoxicillin were equivalent to such rates among similar children receiving placebo.
Current guidelines are based on the concern that pneumonia causes death in more children in the developing countries than any other disease, and in situations lacking access to laboratory investigations, tachypnea can be used as a surrogate for the diagnosis of pneumonia. There are no randomized, placebocontrolled trials comparing the usefulness of antibiotics in children classified as having nonsevere pneumonia. Our study is, to our knowledge, the first double-blinded, randomized, placebo-controlled trial providing scientific evidence performing similar trials in diverse settings of developing countries that have a high burden of pneumonia. The results of these studies, if similar, could form the basis for changing the current WHO recommendations. This will further rationalize the use of antibiotics in one of the common childhood illnesses, thereby reducing pressure on antimicrobial resistance, which is becoming a real problem for the program in developing countries [16, 17] . Our study had a high proportion of wheezers. Because of the well-known association of wheeze with viral pneumonias, particularly RSV bronchiolitis [629] , it is likely that this high incidence of wheeze is actually a reflection of changing epidemiology of pneumonia in developing countries. Current WHO guidelines take cognizance of this fact and, to avoid overcategorization of pneumonia and rationalize the use of antibiotics in children with audible wheeze, recommend giving 2 cycles of rapidly acting inhaled bronchodilators at 15-min intervals before reassessment for antibiotic administration. This recommendation has shown to be useful [18] , but there are still some unresolved issues. Data show that 70% of the children with auscultatory wheeze do not have audible wheeze [18] and, therefore, are being excluded from a trial of bronchodilators before assessment. Moreover, bronchodilators are not effective in bronchiolitis [19, 20] . Our results provide evidence that can be used for developing a more pragmatic management algorithm for children with wheeze.
There could be a concern that many children with fast breathing may have bacterial pneumonia and, therefore, will be denied the benefit of antibiotic therapy. Of interest, that rate of subsequent deterioration in both arms suggests that giving amoxicillin to these children with fast breathing has no protective effect on the subsequent course of illness. Greater emphasis, therefore, is needed for closer follow-up and better counseling of the caregivers of these children, so that the children at high risk can be identified in time and the appropriate treatment is initiated. Moreover, further study is needed on the characteristics of these children to better understand the reasons for failure. Determinants of subsequent deterioration can then be used in a model to identify children at high risk at the time of presentation.
There are certain strengths and limitations of our study. The loss to follow-up was only 2%. No deaths were reported in our study because of the improved training of the study staff in acute respiratory illness case management and close follow-up at home if the patient failed to visit at the health facility. This again highlights the importance of close monitoring and good followup.
Our study did not include microbiologis analysis, thereby adding little to the existing knowledge of the prevalent etiologic agents in developing countries. Because this randomized controlled trial was not intended to evaluate the effectiveness of antibiotics in possible bacterial pneumonia but was an evaluation of performance of current WHO acute respiratory illness case management guidelines, performing any investigation before antibiotic prescription would have diverted us from the purpose of our analysis. In this randomized controlled trial, WHO guidelines were followed in exactly the same way as they are being practiced in the community.
We conclude that our results strongly suggest that the benefit of antibiotics in children 2-59 months of age who are have WHO-defined nonsevere pneumonia is questionable. Further research from developing countries is needed to validate the results of this study. If validated, the use of antibiotics in WHO current guidelines can be further rationalized. 
